TAM
CBAY

Tiverton Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Tiverton Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$41K Hold
7,948
– – ﹤0.01% 697
2019
Q2 		$57K Hold
7,948
– – ﹤0.01% 660
2019
Q1 		$105K Hold
7,948
– – ﹤0.01% 575
2018
Q4 		$63K Buy
+7,948
New +$75.7K ﹤0.01% 428

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Tiverton Asset Management's CBAY Position: Q3 2019 in Review

Tiverton Asset Management held its Cymabay Therapeutics (CBAY) position steady in Q3 2019 at 7,948 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #697.

Tiverton Asset Management first reported a position in CBAY in Q4 2018 and has held it in 4 quarters since. The position peaked at $105K in Q1 2019. 137 funds tracked by Wall St. Rank hold CBAY as of Q3 2019.

  • Tiverton Asset Management held 7,948 shares of Cymabay Therapeutics worth $41K as of Q3 2019.
  • Tiverton Asset Management left its Cymabay Therapeutics share count unchanged in Q3 2019.
  • Cymabay Therapeutics made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #697 holding.
  • Tiverton Asset Management first reported a position in Cymabay Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Tiverton Asset Management's Cymabay Therapeutics position peaked at $105K in Q1 2019.
  • 137 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.